VCYT
Veracyte, Inc. NASDAQ Listed Oct 30, 2013$53.63
+4.56%
vs $51.29
Mkt Cap $4.3B
52w Low $23.03
100.0% of range
52w High $53.63
50d MA $40.73
200d MA $38.43
P/E (TTM)
49.1x
EV/EBITDA
34.8x
P/B
3.2x
Debt/Equity
0.0x
ROE
5.1%
P/FCF
34.1x
RSI (14)
71.20
ATR (14)
$2.44
Beta
1.96
50d MA
$40.73
200d MA
$38.43
Avg Volume
1.3M
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
6000 Shoreline Court · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.34 | 0.36 | +5.9% | 32.97 | +18.3% | +24.9% | -1.0% | -0.8% | -1.8% | -0.4% | — |
| Feb 25, 2026 | AMC | 0.41 | 0.53 | +29.8% | 35.72 | +7.8% | +8.5% | -5.6% | -1.6% | -2.6% | +3.4% | — |
| Nov 4, 2025 | AMC | 0.32 | 0.51 | +59.4% | 36.12 | +10.7% | +27.5% | -9.4% | +0.0% | +1.6% | +0.7% | — |
| Aug 6, 2025 | AMC | 0.31 | 0.44 | +41.9% | 23.97 | +8.5% | +15.5% | -1.1% | +2.3% | +2.8% | +6.6% | — |
| May 7, 2025 | AMC | 0.20 | 0.31 | +55.0% | 30.84 | -2.1% | +1.2% | -4.8% | +3.5% | -4.7% | -2.8% | — |
| Feb 24, 2025 | AMC | 0.10 | 0.36 | +260.0% | 39.36 | -8.3% | -15.0% | +6.2% | -4.8% | +2.7% | -3.5% | — |
| Nov 6, 2024 | AMC | 0.03 | 0.19 | +603.7% | 36.59 | +8.5% | +2.0% | -2.3% | +6.6% | -1.7% | +3.4% | — |
| Aug 6, 2024 | AMC | 0.05 | 0.30 | +530.7% | 21.82 | +20.1% | +24.0% | +10.8% | -2.3% | +2.2% | +8.8% | — |
| May 7, 2024 | AMC | -0.19 | -0.02 | +89.5% | 21.03 | +3.1% | -4.3% | +2.5% | +3.6% | +5.3% | +2.3% | — |
| Feb 22, 2024 | AMC | -0.07 | -0.04 | +42.9% | 24.34 | -2.2% | -8.9% | +6.2% | +0.3% | +0.6% | -0.9% | — |
| Nov 7, 2023 | AMC | -0.16 | -0.03 | +81.2% | 24.01 | +3.9% | -3.6% | -7.3% | +3.4% | +3.4% | +10.0% | — |
| Aug 8, 2023 | AMC | -0.16 | -0.12 | +25.0% | 25.00 | +5.9% | +7.0% | -4.9% | -1.1% | +0.8% | -1.3% | — |
| May 4, 2023 | AMC | -0.14 | -0.11 | +21.4% | 22.26 | +3.2% | +4.6% | -2.8% | +1.5% | +3.0% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2 | Wolfe Research | Reiterates | Outperform | $55 | $48.18 | $48.17 | -0.0% | -0.8% | +1.9% | +2.6% | -2.4% | -3.0% |
| Apr 20 | Canaccord Genuity | Maintains | Hold → Hold | — | $33.80 | $33.35 | -1.3% | -1.0% | +0.2% | +0.6% | -1.7% | +3.6% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $32.21 | $32.31 | +0.3% | +0.6% | -0.5% | +0.2% | -0.5% | +1.6% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $30.01 | $30.20 | +0.6% | +1.4% | +5.8% | +0.6% | -0.5% | +0.2% |
| Mar 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $34.68 | $33.34 | -3.9% | -2.4% | -1.4% | -1.8% | -1.0% | -4.7% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $35.72 | $38.51 | +7.8% | +8.5% | -5.6% | -1.6% | -2.6% | +3.4% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $42.39 | $42.41 | +0.0% | +2.9% | +4.6% | -1.2% | -3.4% | -3.5% |
| Dec 2 | Morgan Stanley | Maintains | Underweight → Underweight | — | $46.39 | $46.25 | -0.3% | -0.5% | +3.4% | -0.7% | -5.9% | -0.6% |
| Nov 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $42.35 | $42.44 | +0.2% | +0.7% | -0.8% | -5.7% | -1.3% | -0.2% |
| Nov 5 | Canaccord Genuity | Maintains | Hold → Hold | — | $36.12 | $40.00 | +10.7% | +27.5% | -9.4% | +0.0% | +1.6% | +0.7% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | -9.4% | +0.0% | +1.6% | +0.7% |
| Nov 5 | UBS | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | -9.4% | +0.0% | +1.6% | +0.7% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $36.12 | $40.00 | +10.7% | +27.5% | -9.4% | +0.0% | +1.6% | +0.7% |
| May 8 | UBS | Maintains | Buy → Buy | — | $30.84 | $30.19 | -2.1% | +1.2% | -4.8% | +3.5% | -4.7% | -2.8% |
| May 8 | Needham | Maintains | Buy → Buy | — | $30.84 | $30.19 | -2.1% | +1.2% | -4.8% | +3.5% | -4.7% | -2.8% |
| Apr 9 | Guggenheim | Maintains | Buy → Buy | — | $28.88 | $27.22 | -5.7% | +13.0% | -7.3% | +5.1% | +1.1% | -1.2% |
| Mar 26 | Stephens & Co. | Maintains | Overweight → Overweight | — | $33.69 | $33.60 | -0.3% | -7.8% | +0.2% | -3.2% | -1.6% | -0.3% |
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $39.36 | $36.10 | -8.3% | -15.0% | +6.2% | -4.8% | +2.7% | -3.5% |
| Feb 25 | UBS | Maintains | Buy → Buy | — | $39.36 | $36.10 | -8.3% | -15.0% | +6.2% | -4.8% | +2.7% | -3.5% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $39.36 | $36.10 | -8.3% | -15.0% | +6.2% | -4.8% | +2.7% | -3.5% |
| Jan 29 | Needham | Maintains | Buy → Buy | — | $43.67 | $44.30 | +1.4% | +1.8% | +3.8% | -1.4% | -0.9% | -2.9% |
| Dec 5 | Goldman Sachs | Downgrade | Buy → Neutral | — | $44.09 | $42.00 | -4.7% | -2.8% | +3.0% | -3.1% | +0.5% | +1.2% |
| Nov 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $35.94 | $36.05 | +0.3% | +2.1% | +6.6% | +0.1% | -0.7% | +1.7% |
| Nov 8 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $37.34 | $37.15 | -0.5% | -2.3% | +6.6% | -1.7% | +3.4% | -6.3% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $36.59 | $39.70 | +8.5% | +2.0% | -2.3% | +6.6% | -1.7% | +3.4% |
| Nov 7 | UBS | Maintains | Buy → Buy | — | $36.59 | $39.70 | +8.5% | +2.0% | -2.3% | +6.6% | -1.7% | +3.4% |
| Nov 7 | Goldman Sachs | Maintains | Buy → Buy | — | $36.59 | $39.70 | +8.5% | +2.0% | -2.3% | +6.6% | -1.7% | +3.4% |
| Oct 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $34.72 | $34.78 | +0.2% | -1.2% | +0.4% | -3.8% | -1.6% | -0.5% |
| Aug 28 | Needham | Maintains | Buy → Buy | — | $32.00 | $32.14 | +0.4% | -1.2% | +1.0% | -1.2% | -4.0% | -2.4% |
| Aug 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $29.27 | $29.84 | +1.9% | +2.2% | +8.8% | -4.2% | +4.7% | +0.6% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $21.82 | $26.20 | +20.1% | +24.0% | +10.8% | -2.3% | +2.2% | +8.8% |
| May 8 | Needham | Maintains | Buy → Buy | — | $21.03 | $21.68 | +3.1% | -4.3% | +2.5% | +3.6% | +5.3% | +2.3% |
| Apr 15 | Goldman Sachs | Maintains | Buy → Buy | — | $20.23 | $20.18 | -0.2% | -4.3% | -2.3% | -0.3% | +1.8% | +1.3% |
| Feb 26 | Morgan Stanley | Maintains | Underweight → Underweight | — | $22.18 | $21.88 | -1.4% | +6.2% | +0.3% | +0.6% | -0.9% | +1.9% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $24.34 | $23.80 | -2.2% | -8.9% | +6.2% | +0.3% | +0.6% | -0.9% |
| Nov 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $21.47 | $21.45 | -0.1% | +3.4% | +3.4% | +10.0% | -0.9% | -1.2% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $24.01 | $24.94 | +3.9% | -3.6% | -7.3% | +3.4% | +3.4% | +10.0% |
| Oct 23 | Goldman Sachs | Maintains | Buy → Buy | — | $20.93 | $20.63 | -1.4% | -0.8% | +3.4% | -7.0% | +2.4% | -3.4% |
| Oct 20 | Goldman Sachs | Maintains | Buy → Buy | — | $20.79 | $20.80 | +0.0% | +0.7% | -0.8% | +3.4% | -7.0% | +2.4% |
| Oct 10 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.87 | $21.97 | +0.5% | +3.2% | -1.1% | -5.8% | +1.2% | +0.0% |
| Aug 9 | Morgan Stanley | Maintains | Underweight → Underweight | — | $25.00 | $26.48 | +5.9% | +7.0% | -4.9% | -1.1% | +0.8% | -1.3% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $25.00 | $26.48 | +5.9% | +7.0% | -4.9% | -1.1% | +0.8% | -1.3% |
| May 8 | Stephens & Co. | Maintains | Overweight → Overweight | — | $23.28 | $23.19 | -0.4% | -2.8% | +1.5% | +3.0% | -0.3% | -0.3% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $23.90 | $26.30 | +10.0% | +0.1% | -0.6% | +1.9% | +1.6% | -3.7% |
| Jan 18 | Raymond James | Downgrade | Outperform → Market Perform | — | $26.69 | $25.88 | -3.0% | -2.9% | -7.6% | +4.0% | +5.7% | -1.7% |
| Jan 5 | Scotiabank | Maintains | Sector Outperform → Outperform | — | $23.77 | $23.92 | +0.6% | -2.8% | -3.1% | +3.0% | +4.0% | +5.1% |
| Nov 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $24.23 | $24.50 | +1.1% | +0.6% | +1.4% | +0.9% | -7.5% | +21.1% |
| Nov 4 | Raymond James | Maintains | Outperform → Outperform | — | $24.23 | $24.50 | +1.1% | +0.6% | +1.4% | +0.9% | -7.5% | +21.1% |
| Nov 3 | SVB Leerink | Maintains | Outperform → Outperform | — | $19.50 | $22.98 | +17.8% | +24.3% | +0.6% | +1.4% | +0.9% | -7.5% |
| Nov 3 | Needham | Maintains | Buy → Buy | — | $19.50 | $22.98 | +17.8% | +24.3% | +0.6% | +1.4% | +0.9% | -7.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Stapley MarcDir/Off | Chief Executive Officer | Sell | 138,051 | $50.12 | $6.9M | 440,494 | -2.42% | -1.56% |
| Jun 4, 2026 | Chambers RebeccaOff | Chief Financial Officer | Sell | 1,961 | $50.09 | $98K | 173,280 | -2.42% | -1.56% |
| Jun 4, 2026 | Chambers RebeccaOff | Chief Financial Officer | Sell | 1,600 | $49.28 | $79K | 175,241 | -2.42% | -1.56% |
| Jun 4, 2026 | McGuire AnnieOff | EVP, General Counsel | Sell | 1,776 | $50.12 | $89K | 137,240 | -2.42% | -1.56% |
| Jun 4, 2026 | McGuire AnnieOff | EVP, General Counsel | Sell | 1,400 | $49.31 | $69K | 139,016 | -2.42% | -1.56% |
| Jun 4, 2026 | Leite JohnOff | Global Chief Commercial Off | Sell | 13,975 | $50.07 | $700K | 132,305 | -2.42% | -1.56% |
| May 22, 2026 | Wygant JonathanOff | VP, Chief Accounting Officer | Sell | 24,000 | $45.40 | $1.1M | 45,434 | +7.87% | +1.86% |
| May 6, 2026 | McGuire AnnieOff | SVP, General Counsel | Sell | 5,102 | $38.05 | $194K | 148,810 | -1.78% | -1.08% |
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Leadership transitions with equity incentives can signal confidence in succession planning, but investors should monitor whether new executives meet performance targets to ensure shareholder value isn't diluted through excessive equity grants.
Mar 16
8-K
Veracyte, Inc. -- 8-K Filing
Veracyte's fourth quarter testing revenue grew 21% to $135.8 million, demonstrating strong operational momentum in its diagnostic testing business.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 7,763,849 | $250M | Added | Mar 2026 |
| 2 | Artisan Partners Limited Partnership | 5,496,370 | $177M | Reduced | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 4,444,730 | $143M | New | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 3,532,232 | $114M | New | Mar 2026 |
| 5 | Morgan Stanley | 2,366,138 | $100M | Added | Dec 2025 |
| 6 | Ark Investment Management Llc | 3,053,818 | $98M | Reduced | Mar 2026 |
| 7 | First Trust Advisors Lp | 2,117,046 | $68M | Added | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 1,448,897 | $47M | Added | Mar 2026 |
| 9 | William Blair Investment Management, Llc | 989,687 | $32M | Added | Mar 2026 |
| 10 | Northern Trust Corp | 929,500 | $30M | Reduced | Mar 2026 |
| 11 | Alyeska Investment Group, L.p. | 808,570 | $26M | Added | Mar 2026 |
| 12 | Deerfield Management Company, L.p. | 726,000 | $23M | — | Mar 2026 |
| 13 | Principal Financial Group Inc | 465,384 | $20M | Added | Dec 2025 |
| 14 | Segall Bryant & Hamill, Llc | 591,488 | $19M | New | Mar 2026 |
| 15 | Royal Bank Of Canada | 573,096 | $18M | Added | Mar 2026 |
| 16 | Point72 Asset Management | 483,904 | $16M | Added | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 496,219 | $15M | Reduced | Mar 2026 |
| 18 | Silverarc Capital Management, Llc | 357,558 | $15M | Added | Dec 2025 |
| 19 | Invesco Ltd. | 436,587 | $14M | Added | Mar 2026 |
| 20 | Sei Investments Co | 420,093 | $14M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$4.32B
Enterprise Value
$3.91B
P/E (TTM)
49.10x
Forward P/E
32.33x
PEG Ratio
0.31x
P/B
3.22x
P/S
7.98x
P/FCF
34.12x
EV/EBITDA
34.82x
Shares Out
80.6M
Financials (TTM)
Revenue
$541.7M
Net Income
$88.0M
EBITDA
$112.2M
Free Cash Flow
$126.6M
Op Cash Flow
$136.3M
EPS Basic
$0.84
EPS Diluted
$1.08
EPS Forward
$1.66
Gross Margin
71.3%
Op Margin
12.4%
Net Margin
16.2%
Balance Sheet
Total Assets
$1.41B
Total Liab.
$96.4M
Total Equity
$1.31B
Cash
$412.9M
LT Debt
$0
Book Value/Sh
$16.66
Debt/Equity
0.03x
Current Ratio
8.15
Quick Ratio
7.81
Returns & Growth
ROE
5.1%
ROA
4.7%
ROIC
5.3%
Rev Growth YoY
+16.0%
EPS Growth YoY
+162.5%
Price Returns
2W
+19.1%
1M
+40.8%
3M
+26.6%
6M
-2.1%
12M
+74.1%
Technicals
52W High
$53.63
52W Low
$23.03
50d MA
$40.73
200d MA
$38.43
RSI (14)
71.20
ATR (14)
$2.44
Beta
1.96
Avg Volume
1.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$44.50
High
$50.00
Low
$37.00
Median
$45.50
Data updated apr 27, 2026 7:27am
· Source: financialmodelingprep.com